AA
VKTX icon

AlphaMark Advisors’s Viking Therapeutics VKTX Stock Holding History

AlphaMark Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-155
Closed -$10K – 734
2024
Q3 		$10K Buy
+155
New +$9.09K ﹤0.01% 517
2020
Q3 		– Sell
-200
Closed -$1K – 566
2020
Q2 		$1K Hold
200
– – ﹤0.01% 524
2020
Q1 		$1K Hold
200
– – ﹤0.01% 548
2019
Q4 		$2K Hold
200
– – ﹤0.01% 456
2019
Q3 		$1K Hold
200
– – ﹤0.01% 474
2019
Q2 		$2K Hold
200
– – ﹤0.01% 477
2019
Q1 		$2K Hold
200
– – ﹤0.01% 462
2018
Q4 		$2K Sell
200
-200
-50% -$2.39K ﹤0.01% 444
2018
Q3 		$7K Buy
+400
New +$4.76K ﹤0.01% 393

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AlphaMark Advisors's VKTX Position: Q4 2024 in Review

AlphaMark Advisors sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 155 shares — an estimated $10K sold.

AlphaMark Advisors first reported a position in VKTX in Q3 2018 and held it in 9 quarters. The position peaked at $10K in Q3 2024. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • AlphaMark Advisors reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AlphaMark Advisors sold 155 Viking Therapeutics shares in Q4 2024, an estimated $10K.
  • AlphaMark Advisors first reported a position in Viking Therapeutics in Q3 2018 and held it in 9 quarters.
  • AlphaMark Advisors's Viking Therapeutics position peaked at $10K in Q3 2024.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.